243 related articles for article (PubMed ID: 36283607)
1. Asthma Management in Adults.
Busse WW; Castro M; Casale TB
J Allergy Clin Immunol Pract; 2023 Jan; 11(1):21-33. PubMed ID: 36283607
[TBL] [Abstract][Full Text] [Related]
2. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database.
Cutroneo PM; Arzenton E; Furci F; Scapini F; Bulzomì M; Luxi N; Caminati M; Senna G; Moretti U; Trifirò G
BioDrugs; 2024 May; 38(3):425-448. PubMed ID: 38489062
[TBL] [Abstract][Full Text] [Related]
3. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
[TBL] [Abstract][Full Text] [Related]
5. Biological treatments for severe asthma: A major advance in asthma care.
Busse WW
Allergol Int; 2019 Apr; 68(2):158-166. PubMed ID: 30792118
[TBL] [Abstract][Full Text] [Related]
6. [Biologics for the treatment of severe asthma: Current status report 2023].
Paçacı Çetin G; Kepil Özdemir S; Can Bostan Ö; Öztop N; Çelebi Sözener Z; Karakaya G; Gelincik Akkor A; Yılmaz İ; Mungan D; Bavbek S
Tuberk Toraks; 2023 Jun; 71(2):176-187. PubMed ID: 37345400
[TBL] [Abstract][Full Text] [Related]
7. New perspectives of childhood asthma treatment with biologics.
Just J; Deschildre A; Lejeune S; Amat F
Pediatr Allergy Immunol; 2019 Mar; 30(2):159-171. PubMed ID: 30444939
[TBL] [Abstract][Full Text] [Related]
8. Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison.
Menzies-Gow A; Steenkamp J; Singh S; Erhardt W; Rowell J; Rane P; Martin N; Ackert JL; Quinton A
J Med Econ; 2022; 25(1):679-690. PubMed ID: 35570578
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Biologics for Oral Corticosteroid-Dependent Asthma: A Systematic Review and Network Meta-Analysis.
Phinyo P; Krikeerati T; Vichara-Anont I; Thongngarm T
J Allergy Clin Immunol Pract; 2024 Feb; 12(2):409-420. PubMed ID: 37972921
[TBL] [Abstract][Full Text] [Related]
10. Biologics in the treatment of asthma in children and adolescents.
Bacharier LB; Jackson DJ
J Allergy Clin Immunol; 2023 Mar; 151(3):581-589. PubMed ID: 36702649
[TBL] [Abstract][Full Text] [Related]
11. Biologic use and outcomes among adults with severe asthma treated by US subspecialists.
Panettieri RA; Ledford DK; Chipps BE; Soong W; Lugogo N; Carr W; Mohan A; Carstens D; Genofre E; Trudo F; Ambrose CS
Ann Allergy Asthma Immunol; 2022 Oct; 129(4):467-474.e3. PubMed ID: 35728746
[TBL] [Abstract][Full Text] [Related]
12. Targeting Downstream Type 2 Cytokines or Upstream Epithelial Alarmins for Severe Asthma.
Chan R; Stewart K; Misirovs R; Lipworth BJ
J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1497-1505. PubMed ID: 35131510
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of dupilumab among patients with oral corticosteroid-dependent uncontrolled severe asthma in Japan.
Tohda Y; Matsumoto H; Miyata M; Taguchi Y; Ueyama M; Joulain F; Arakawa I
J Asthma; 2022 Nov; 59(11):2162-2173. PubMed ID: 34752208
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Biologics in Patients with Allergic Severe Asthma, Overall and by Blood Eosinophil Count: A Literature Review.
Bernstein JA; Llanos JP; Hunter G; Martin N; Ambrose CS
Adv Ther; 2023 Nov; 40(11):4721-4740. PubMed ID: 37698716
[TBL] [Abstract][Full Text] [Related]
15. Clinical effects and immune modulation of biologics in asthma.
Harada N; Ito J; Takahashi K
Respir Investig; 2021 Jul; 59(4):389-396. PubMed ID: 33893067
[TBL] [Abstract][Full Text] [Related]
16. Pragmatic Clinical Perspective on Biologics for Severe Refractory Type 2 Asthma.
Chan R; RuiWen Kuo C; Lipworth B
J Allergy Clin Immunol Pract; 2020; 8(10):3363-3370. PubMed ID: 32673880
[TBL] [Abstract][Full Text] [Related]
17. Precision care in the treatment of pediatric asthma.
Mahmood L; Keskin S; Jefferson AA
Curr Opin Pediatr; 2024 Jun; 36(3):304-309. PubMed ID: 38411592
[TBL] [Abstract][Full Text] [Related]
18. Severe asthma: When to resort to biological agents.
Tenero L; Rossignoli S; Piacentini G
Pediatr Allergy Immunol; 2020 Feb; 31 Suppl 24():37-39. PubMed ID: 32017206
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and Management of Asthma in Adults: A Review.
McCracken JL; Veeranki SP; Ameredes BT; Calhoun WJ
JAMA; 2017 Jul; 318(3):279-290. PubMed ID: 28719697
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of biologic therapy on airway hyperresponsiveness in asthma.
Chan R; Lipworth B
Ann Allergy Asthma Immunol; 2023 Jul; 131(1):37-41. PubMed ID: 36841374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
